PAMELA INGRAM: Open Payments
NPI 1508193855 · DU BOIS, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,340 in 71 payments from 30 companies in 2025. Trend: 2023 $1,435 · 2024 $1,329 · 2025 $1,340
Food & beverage: $1,340
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 6 | $129 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $99 |
| Incyte Corporation | 4 | $77 |
| Exelixis Inc. | 4 | $75 |
| Merck Sharp & Dohme LLC | 3 | $69 |
| ABBVIE INC. | 3 | $69 |
| Novartis Pharmaceuticals Corporation | 4 | $65 |
| GlaxoSmithKline, LLC. | 3 | $64 |
| ARRAY BIOPHARMA INC | 3 | $50 |
| Eisai Inc. | 2 | $50 |
Products named: CABOMETYX, KEYTRUDA, JAKAFI, Xtandi, ERLEADA, Lenvima, TAVALISSE, RYTELO.
Industry payments across PA — which companies pay providers there.
